Solid Biosciences Inc (SLDB)

$5.77 -0.15 (-2.53%)
Market Cap 449.54M
Revenue (ttm) 0.00
Net Income (ttm) -124.70M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,106,600
Avg Vol 1,129,212
Day's Range N/A - N/A
Shares Out 77.91M
Stochastic %K 75%
Beta 2.97
Analysts Strong Sell
Price Target $15.23

Company Profile

Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It also develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopath...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 337 4680
Address:
500 Rutherford Avenue, Third Floor, Charlestown, United States
Jonrenie
Jonrenie Dec. 5 at 11:24 PM
$SLDB stay on target 🎯 *pew pew*
0 · Reply
VegaPulse41
VegaPulse41 Dec. 5 at 8:22 PM
$SLDB biotech with real catalyst potential, can shift sentiment fast
1 · Reply
Bangra
Bangra Dec. 5 at 8:11 PM
$SLDB I added more.
1 · Reply
BluntForceOptions
BluntForceOptions Dec. 5 at 3:22 PM
$SLDB Just a quick follow-up to the Needham bullish call yesterday: the analyst note emphasized strong expression data, no safety concerns so far, an improved competitive lane in DMD, and a healthy runway into 2027. Adds more context for those following the stock.
0 · Reply
Tradeforincome
Tradeforincome Dec. 5 at 2:51 PM
$SLDB I’m in. Will sell in the next PR though. Quick swing trade before year end.
0 · Reply
pharmd2828
pharmd2828 Dec. 5 at 12:39 PM
$SLDB should get through R3 Fibonacci 6.59 then breeze into 7.20s ..imho ..plz do DD
0 · Reply
The_Red_Fox
The_Red_Fox Dec. 5 at 11:27 AM
$SLDB Trend-wise, it looks like February's quick doubling and June 3-4 week +70% run... plus the news has been very good this week. Broader market future are also up nicely today. I'm adding here in the pre-market at 0700 - seems like a good time to fully position. The pipeline is starting to deliver: capsid orders, 212 ODD, and some pending news on 003 could come any day (but probably a couple of months off, realistically), on the back of some very positive (though low n) early trial results and the UK pathway designation. I like that they have taken a cautious approach to safety on the 003 critical program. Stay patient!
0 · Reply
TradeHawk
TradeHawk Dec. 4 at 11:55 PM
$SLDB Solid Biosciences has received FDA Orphan Drug Designation for SGT-212 for treatment of Friedreich's ataxia. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1108025
1 · Reply
Jonrenie
Jonrenie Dec. 4 at 9:50 PM
$SLDB patience.
1 · Reply
Bangra
Bangra Dec. 4 at 8:47 PM
$SLDB This is probably not the turn of events that short sellers expected. Low volume means it will take them a long time to return the borrowed shares, and there are few of them.
0 · Reply
Latest News on SLDB
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 1, 2025, 4:05 PM EST - 6 days ago

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Solid Biosciences Receives FDA Rare Pediatric Disease Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich's Ataxia

Dec 1, 2025, 8:00 AM EST - 6 days ago

Solid Biosciences Receives FDA Rare Pediatric Disease Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich's Ataxia

Solid Biosciences Announces Licensing Agreement with Andelyn Biosciences for the Use of Proprietary Next-Generation Capsid AAV-SLB101

Nov 17, 2025, 8:00 AM EST - 20 days ago

Solid Biosciences Announces Licensing Agreement with Andelyn Biosciences for the Use of Proprietary Next-Generation Capsid AAV-SLB101

Solid Biosciences to Participate at Upcoming Investor Conferences

Nov 11, 2025, 8:00 AM EST - 26 days ago

Solid Biosciences to Participate at Upcoming Investor Conferences

Solid Biosciences Awarded Innovation Passport Designation Under the New UK Innovative Licensing and Access Pathway for SGT-003, an Investigational Gene Therapy for Duchenne Muscular Dystrophy

Nov 6, 2025, 8:00 AM EST - 4 weeks ago

Solid Biosciences Awarded Innovation Passport Designation Under the New UK Innovative Licensing and Access Pathway for SGT-003, an Investigational Gene Therapy for Duchenne Muscular Dystrophy

Solid Biosciences Reports Third Quarter 2025 Financial Results and Provides Update on INSPIRE DUCHENNE Clinical Trial Progress and Planned Regulatory Discussions

Nov 3, 2025, 4:05 PM EST - 4 weeks ago

Solid Biosciences Reports Third Quarter 2025 Financial Results and Provides Update on INSPIRE DUCHENNE Clinical Trial Progress and Planned Regulatory Discussions

Solid Biosciences to Present at Upcoming Scientific Meetings

Oct 1, 2025, 8:00 AM EDT - 2 months ago

Solid Biosciences to Present at Upcoming Scientific Meetings

Solid Biosciences to Present at 2025 Neuromuscular Study Group Annual Scientific Meeting

Sep 25, 2025, 8:00 AM EDT - 2 months ago

Solid Biosciences to Present at 2025 Neuromuscular Study Group Annual Scientific Meeting

Solid Biosciences Announces Licensing Agreement with Kinea Bio for the Use of Proprietary Next-Generation Capsid AAV-SLB101

Sep 23, 2025, 8:00 AM EDT - 2 months ago

Solid Biosciences Announces Licensing Agreement with Kinea Bio for the Use of Proprietary Next-Generation Capsid AAV-SLB101

Kinea Bio Secures $1.1M Jain Foundation Investment and Solid Biosciences Capsid License to Advance Novel Gene Therapy for Dysferlinopathy, a Rare Neuromuscular Disease

Sep 23, 2025, 8:00 AM EDT - 2 months ago

Kinea Bio Secures $1.1M Jain Foundation Investment and Solid Biosciences Capsid License to Advance Novel Gene Therapy for Dysferlinopathy, a Rare Neuromuscular Disease

Solid Biosciences Inc. (SLDB) Presents At Citi's Biopharma Back To School Conference Transcript

Sep 2, 2025, 4:28 PM EDT - 3 months ago

Solid Biosciences Inc. (SLDB) Presents At Citi's Biopharma Back To School Conference Transcript

Solid Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Updates

Aug 12, 2025, 4:07 PM EDT - 4 months ago

Solid Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Updates

Solid Biosciences Receives FDA Fast Track Designation for SGT-501 First-in-Class Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

Jul 23, 2025, 8:00 AM EDT - 4 months ago

Solid Biosciences Receives FDA Fast Track Designation for SGT-501 First-in-Class Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

Solid Biosciences: SGT-003's Safety Profile Illuminates DMD Gene Therapy Path (Rating Upgrade)

Jul 11, 2025, 3:02 PM EDT - 5 months ago

Solid Biosciences: SGT-003's Safety Profile Illuminates DMD Gene Therapy Path (Rating Upgrade)

SHAREHOLDER NOTICE: Kaskela Law LLC Announces Shareholder Investigation of Solid Biosciences Inc. (NASDAQ: SLDB) and Encourages Long-Term SLDB Investors to Contact the Firm

Jul 10, 2025, 8:00 AM EDT - 5 months ago

SHAREHOLDER NOTICE: Kaskela Law LLC Announces Shareholder Investigation of Solid Biosciences Inc. (NASDAQ: SLDB) and Encourages Long-Term SLDB Investors to Contact the Firm

Solid Biosciences Announces FDA IND and Health Canada CTA Approval for First-in-Class Cardiac Gene Therapy to Treat Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

Jul 8, 2025, 4:05 PM EDT - 5 months ago

Solid Biosciences Announces FDA IND and Health Canada CTA Approval for First-in-Class Cardiac Gene Therapy to Treat Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

Solid Biosciences to Participate at the Jefferies Global Healthcare Conference

May 28, 2025, 8:00 AM EDT - 6 months ago

Solid Biosciences to Participate at the Jefferies Global Healthcare Conference

Solid Biosciences Reports First Quarter 2025 Financial Results and Provides Business Updates

May 15, 2025, 4:06 PM EDT - 7 months ago

Solid Biosciences Reports First Quarter 2025 Financial Results and Provides Business Updates

Solid Biosciences to Participate at The Citizens Life Sciences Conference

Apr 30, 2025, 8:00 AM EDT - 7 months ago

Solid Biosciences to Participate at The Citizens Life Sciences Conference

Solid Biosciences to Present at the American Society of Gene and Cell Therapy's 28th Annual Meeting

Apr 29, 2025, 8:00 AM EDT - 7 months ago

Solid Biosciences to Present at the American Society of Gene and Cell Therapy's 28th Annual Meeting

Solid Biosciences: A Strong Buy As An Emerging Biotech In The Gene Therapy Space

Apr 8, 2025, 4:50 PM EDT - 8 months ago

Solid Biosciences: A Strong Buy As An Emerging Biotech In The Gene Therapy Space

Drug stocks sink as FDA's top vaccine official is ousted in Trump overhaul

Mar 31, 2025, 2:25 PM EDT - 8 months ago

Drug stocks sink as FDA's top vaccine official is ousted in Trump overhaul

BNTX NVAX SRPT TSHA XBI

Solid Biosciences to Present at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Mar 12, 2025, 8:00 AM EDT - 9 months ago

Solid Biosciences to Present at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Solid Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Mar 6, 2025, 4:16 PM EST - 9 months ago

Solid Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Solid Biosciences Stock Surges On Upbeat Duchenne Muscular Dystrophy Gene Therapy Data

Feb 18, 2025, 12:29 PM EST - 10 months ago

Solid Biosciences Stock Surges On Upbeat Duchenne Muscular Dystrophy Gene Therapy Data

Solid Biosciences Announces Pricing of Underwritten Offering

Feb 18, 2025, 7:00 AM EST - 10 months ago

Solid Biosciences Announces Pricing of Underwritten Offering

Solid Biosciences Reports Positive Initial Clinical Data from Next-Generation Duchenne Gene Therapy Candidate SGT-003

Feb 18, 2025, 6:45 AM EST - 10 months ago

Solid Biosciences Reports Positive Initial Clinical Data from Next-Generation Duchenne Gene Therapy Candidate SGT-003

Solid Biosciences: Differentiating Factors Of SGT-212 To Set Itself Apart

Jan 21, 2025, 6:27 PM EST - 11 months ago

Solid Biosciences: Differentiating Factors Of SGT-212 To Set Itself Apart

Solid Biosciences Receives FDA Fast Track Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich's Ataxia

Jan 21, 2025, 8:30 AM EST - 11 months ago

Solid Biosciences Receives FDA Fast Track Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich's Ataxia

Solid Biosciences Outlines Key Priorities for Advancing Diversified Neuromuscular and Cardiac Development Pipeline and Establishing Leadership in Precision Genetic Medicines

Jan 15, 2025, 4:05 PM EST - 11 months ago

Solid Biosciences Outlines Key Priorities for Advancing Diversified Neuromuscular and Cardiac Development Pipeline and Establishing Leadership in Precision Genetic Medicines

Solid Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 8, 2025, 4:05 PM EST - 11 months ago

Solid Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Solid Biosciences Announces FDA IND Clearance for First-In-Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestations of Friedreich's Ataxia

Jan 7, 2025, 4:15 PM EST - 11 months ago

Solid Biosciences Announces FDA IND Clearance for First-In-Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestations of Friedreich's Ataxia

Solid Biosciences Added to the Nasdaq Biotechnology Index

Dec 23, 2024, 4:05 PM EST - 1 year ago

Solid Biosciences Added to the Nasdaq Biotechnology Index

Solid Biosciences Positioned For Next-Gen Duchenne Muscular Dystrophy Treatment Success: Analyst

Dec 13, 2024, 1:52 PM EST - 1 year ago

Solid Biosciences Positioned For Next-Gen Duchenne Muscular Dystrophy Treatment Success: Analyst

Solid Biosciences to Present at the Jefferies London Healthcare Conference

Nov 14, 2024, 8:00 AM EST - 1 year ago

Solid Biosciences to Present at the Jefferies London Healthcare Conference

Solid Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Updates

Nov 6, 2024, 4:05 PM EST - 1 year ago

Solid Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Updates

Solid Biosciences to Participate at the 2024 Cantor Global Healthcare Conference

Sep 12, 2024, 8:00 AM EDT - 1 year ago

Solid Biosciences to Participate at the 2024 Cantor Global Healthcare Conference

Solid Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Updates

Aug 13, 2024, 4:08 PM EDT - 1 year ago

Solid Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Updates

Solid Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jul 1, 2024, 4:19 PM EDT - 1 year ago

Solid Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Solid Biosciences Provides First Quarter 2024 Business Update and Financial Results

May 15, 2024, 7:52 AM EDT - 1 year ago

Solid Biosciences Provides First Quarter 2024 Business Update and Financial Results

Buy Solid Biosciences: Unpacking Its Main Value Driver

Apr 10, 2024, 7:32 PM EDT - 1 year ago

Buy Solid Biosciences: Unpacking Its Main Value Driver

Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003

Apr 1, 2024, 7:45 AM EDT - 1 year ago

Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003

Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial Results

Mar 13, 2024, 7:44 AM EDT - 1 year ago

Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial Results

Solid Biosciences: DMD Treatment Advancement With Next-Generation Capsid

Jan 16, 2024, 11:01 PM EST - 2 years ago

Solid Biosciences: DMD Treatment Advancement With Next-Generation Capsid

Solid Biosciences Granted FDA Orphan Drug Designation for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003

Jan 16, 2024, 8:00 AM EST - 2 years ago

Solid Biosciences Granted FDA Orphan Drug Designation for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003

Solid Biosciences Announces $109 Million Private Placement

Jan 8, 2024, 7:09 AM EST - 2 years ago

Solid Biosciences Announces $109 Million Private Placement

Solid Biosciences to Participate at 35th Annual Piper Sandler Healthcare Conference

Nov 22, 2023, 8:00 AM EST - 2 years ago

Solid Biosciences to Participate at 35th Annual Piper Sandler Healthcare Conference

Solid Biosciences Provides Third Quarter Business Update and Financial Results

Nov 8, 2023, 4:17 PM EST - 2 years ago

Solid Biosciences Provides Third Quarter Business Update and Financial Results

Solid Biosciences Appoints Gabriel Brooks, M.D., as Chief Medical Officer

Oct 2, 2023, 8:00 AM EDT - 2 years ago

Solid Biosciences Appoints Gabriel Brooks, M.D., as Chief Medical Officer

Solid Biosciences Provides Second Quarter Business Update and Financial Results

Aug 14, 2023, 4:17 PM EDT - 2 years ago

Solid Biosciences Provides Second Quarter Business Update and Financial Results

Jonrenie
Jonrenie Dec. 5 at 11:24 PM
$SLDB stay on target 🎯 *pew pew*
0 · Reply
VegaPulse41
VegaPulse41 Dec. 5 at 8:22 PM
$SLDB biotech with real catalyst potential, can shift sentiment fast
1 · Reply
Bangra
Bangra Dec. 5 at 8:11 PM
$SLDB I added more.
1 · Reply
BluntForceOptions
BluntForceOptions Dec. 5 at 3:22 PM
$SLDB Just a quick follow-up to the Needham bullish call yesterday: the analyst note emphasized strong expression data, no safety concerns so far, an improved competitive lane in DMD, and a healthy runway into 2027. Adds more context for those following the stock.
0 · Reply
Tradeforincome
Tradeforincome Dec. 5 at 2:51 PM
$SLDB I’m in. Will sell in the next PR though. Quick swing trade before year end.
0 · Reply
pharmd2828
pharmd2828 Dec. 5 at 12:39 PM
$SLDB should get through R3 Fibonacci 6.59 then breeze into 7.20s ..imho ..plz do DD
0 · Reply
The_Red_Fox
The_Red_Fox Dec. 5 at 11:27 AM
$SLDB Trend-wise, it looks like February's quick doubling and June 3-4 week +70% run... plus the news has been very good this week. Broader market future are also up nicely today. I'm adding here in the pre-market at 0700 - seems like a good time to fully position. The pipeline is starting to deliver: capsid orders, 212 ODD, and some pending news on 003 could come any day (but probably a couple of months off, realistically), on the back of some very positive (though low n) early trial results and the UK pathway designation. I like that they have taken a cautious approach to safety on the 003 critical program. Stay patient!
0 · Reply
TradeHawk
TradeHawk Dec. 4 at 11:55 PM
$SLDB Solid Biosciences has received FDA Orphan Drug Designation for SGT-212 for treatment of Friedreich's ataxia. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1108025
1 · Reply
Jonrenie
Jonrenie Dec. 4 at 9:50 PM
$SLDB patience.
1 · Reply
Bangra
Bangra Dec. 4 at 8:47 PM
$SLDB This is probably not the turn of events that short sellers expected. Low volume means it will take them a long time to return the borrowed shares, and there are few of them.
0 · Reply
wwdxb247
wwdxb247 Dec. 4 at 2:35 PM
$SLDB selling my bag soon
3 · Reply
BluntForceOptions
BluntForceOptions Dec. 4 at 2:33 PM
Needham came out with a Buy and a $16 price target on $SLDB today. Notable endorsement at this range, and my view is the stock probably starts grinding higher from here.
0 · Reply
notreload_ai
notreload_ai Dec. 4 at 1:03 PM
Needham initiates Buy on $SLDB with $16 target, highlighting potential of SGT-003 gene therapy amid concerns over $SRPT Elevidys safety. https://notreload.xyz/needham-starts-coverage-on-solid-biosciences-with-buy-rating/
0 · Reply
pharmd2828
pharmd2828 Dec. 4 at 12:45 PM
$SLDB buy buy hold hold imho …good luck to all
0 · Reply
Bangra
Bangra Dec. 4 at 12:39 PM
$SLDB
0 · Reply
JarvisFlow
JarvisFlow Dec. 4 at 12:02 PM
Needham updates rating for Solid Biosciences ( $SLDB ) to Buy, target set at 16.
0 · Reply
pharmd2828
pharmd2828 Dec. 3 at 6:57 PM
$SLDB shorts should learn a lesson from CAPR skyrocketing move! SLDB pop could be much more explosive since they have more diverse pipelines! They’re not a sole DMD story like other competitors! IMHO
1 · Reply
Dontfuckingcare
Dontfuckingcare Dec. 3 at 5:57 PM
$SLDB amazing they are connected to some worldwide big boys.
1 · Reply
BluntForceOptions
BluntForceOptions Dec. 3 at 3:38 PM
$CAPR’s move is a perfect reminder: in this space, validated results can reset valuation instantly. I’m continuing to add to my $SLDB position. Around $5, with ~16% short float, it’s a clear asymmetric setup where the upside meaningfully outweighs the downside.
0 · Reply
flexdiggs
flexdiggs Dec. 1 at 3:21 PM
$SLDB seems like a fake out by the big guys, i think this gets some traction upwards soon, gl.
1 · Reply
Bangra
Bangra Dec. 1 at 1:11 PM
$SLDB sgt-212 zatwierdzone przez fda🍾
0 · Reply
ProfitsBee
ProfitsBee Dec. 1 at 1:09 PM
$SLDB news out
0 · Reply